YAFI Online Programming // Disease State Management and Drug Therapy

Biologics for Psoriasis

Community Pharmacy Interface with Special Populations

Educational Objectives

After participating in this activity, pharmacists will be able to:

  • LIST the pathogenesis and classification of various forms of psoriasis
  • DESCRIBE comorbidities associated with psoriasis in children and adults
  • DETERMINE the components of individualized treatment plans for pregnant, pediatric, and immunocompromised patients with moderate-to-severe psoriasis based on expert opinion
  • USE this information to expand the pharmacist's role in adherence and monitoring to attain therapeutic treatment goals

After participating in this activity pharmacy technicians will be able to:

  • LIST the basic pathology and symptoms of psoriasis
  • OUTLINE biologic treatments used in psoriasis in special populations
  • IDENTIFY when to refer patients to the pharmacists for recommendations or referrals

Session Offered

Release Date: May 15, 2020

Expiration Date: May 15, 2022

Course Fee

Free

Session Codes

20YC40-JTV58-Pharmacist

20YC40-KBT92-Pharmacy Technician

Accreditation Hours

2.0 hours of CE

Abstract

Psoriasis is a chronic immune-regulated skin disease, often accompanied by several systemic comorbidities. Psoriasis is frequently untreated or undertreated, especially in special populations (pregnant, pediatric, and immunocompromised patients). No clear treatment guidelines exist for special populations because clinical trials usually exclude these patients. Biologics have revolutionized the treatment of psoriasis, with most patients achieving a rapid and complete symptom resolution. Pharmacists and pharmacy technicians can help patients with self-management of psoriasis. Patients need dosing, administration, storage and handling, common adverse effects, and self-management education.

Accreditation Statements

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and pharmacy technicians are eligible to participate in this application-based activity and will receive up to 0.2 CEU (2 contact hours) for completing the activity, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor on- line system and your participation will be recorded with CPE Monitor within 72 hours of submission

ACPE UAN:
0009-0000-20-040-H01-P
0009-0000-20-040-H01-T

Grant funding: Novartis Pharmaceuticals Corp

Cost: Free

Initial Release Date: May 15, 2020

Expiration Date: May 15, 2022

To obtain CPE credit, visit the UConn Online CE Center

Use your NABP E-profile ID and the session code 20YC40-JTV58 for pharmacists or 20YC40-KBT92 for pharmacy technicians to access the online quiz and evaluation.

First- time users must pre-register in the Online CE Center. Test results will be displayed immediately and your participation will be recorded with CPE Mon- itor within 72 hours of completing the requirements.

For questions concerning the online CPE activities, email joanne.nault@uconn.edu

Faculty

Bisni Narayanan, Pharm D, MS, Clinical Specialty Pharmacist, Yale New Haven Health Systems, Outpatient pharmacy services, Hamden, CT

Faculty Disclosure

The author has no actual or potential conflicts of interest associated with this article.

Disclosure of Discussions of Off-label and Investigational Drug Use

This activity may contain discussion of off label/unapproved use of drugs. The content and views presented in this educational program are those of the faculty and do not necessarily represent those of the University of Connecticut School of Pharmacy. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Content

Introduction

Psoriasis is a chronic immune-mediated inflammatory skin condition characterized by a wide range of symptoms. The most common form presents as raised red patches covered with silvery scales and dry, cracked, and thickened skin. In the United States, statisticians estimate psoriasis’s overall prevalence is 3.1%, affecting more than 6.7 million adults who are 20 years and older.1 In 2013, economists estimated its financial burden to be as high as $112 billion annually.2

References

Full List of References

1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512-516. doi:10.1016/j.jaad.2013.11.013
2. Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: A Systematic Review. JAMA Dermatol. 2015;151(6):651-658. doi:10.1001/jamadermatol.2014.3593
3. Shapter L. The treatment of psoriasis by arsenic in large doses. Lancet. 1878;112(2875):474-476.
4. Reid C, Griffiths CEM. Psoriasis and treatment: past, present and future aspects. Acta Derm Venereol. 2020;100(3):adv00032. doi:10.2340/00015555-3386
5. Kim HJ, Lebwohl MG. Biologics and psoriasis: The beat goes on. Dermatol Clin. 2019;37(1):29-36. doi:10.1016/j.det.2018.07.004
6. Seiden E. The history of psoriasis. National Psoriasis Foundation. Avaiable at https://www.psoriasis.org/advance/history-psoriasis. Accessed April 15, 2020.
7. Menter A. Psoriasis and psoriatic arthritis overview. Am J Manag Care. 2016;22(8 Suppl):s216-s224.
8. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. doi:10.3390/ijms20061475
9. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64 Suppl 2(Suppl 2):ii65-ii73. doi:10.1136/ard.2004.031237
10. Gottlieb AB, Ryan C, Murase JE. Clinical considerations for the management of psoriasis in women. Int J Womens Dermatol. 2019;5(3):141-150. doi:10.1016/j.ijwd.2019.04.021
11. Murase JE, Chan KK, Garite TJ, et al. Hormonal effect on psoriasis in pregnancy and post partum. Arch Dermatol. 2005;141(5):601- 606. doi:10.1001/archderm.141.5.601
12. Ferreira C, Azevedo A, Nogueira M, Torres T. Management of psoriasis in pregnancy - a review of the evidence to date. Drugs Context. 2020;9:2019-11-6. doi:10.7573/dic.2019-11-6
13. Johansen CB, Jimenez-Solem E, et al. The use and safety of TNF inhibitors during pregnancy in women with psoriasis: A review. Int J Mol Sci. 2018;19(5):1349. doi:10.3390/ijms19051349
14. Berthelsen BG, Fjeldsøe-Nielsen H, Nielsen CT, Hellmuth E. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatol Oxf Engl. 2010;49(11):2225-2227. doi:10.1093/rheumatology/keq185
15. Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228-233. doi:10.1136/annrheumdis-2017-212196
16. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057
17. Clowse MEB, Scheuerle AE, Chambers C, et al. Pregnancy outcomes after exposure to certolizumab pegol: Updated results from a pharmacovigilance safety database. Arthritis Rheumatol Hoboken NJ. 2018;70(9):1399-1407. doi:10.1002/art.40508
18. Cimzia (certolizumab pegol) [package insert]. Smyrna, GA: UCB; 2012. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125160s270lbl.pdf. Accessed April 15, 2020.
19. Bronckers IMGJ, Paller AS, van Geel MJ, et al. Psoriasis in children and adolescents: Diagnosis, management and comorbidities. Paediatr Drugs. 2015;17:373-384. doi:10.1007/s40272-015-0137-1
20. Cordoro KM, Hitraya-Low M, Taravati K, et al. Skin-infiltrating, interleukin-22-producing T cells differentiate pediatric psoriasis from adult psoriasis. J Am Acad Dermatol. 2017;77(3):417-424.doi:10.1016/j.jaad.2017.05.017
21. Paller S, Lund E. Psoriasis in children: Management of chronic plaque psoriasis. UpToDate. Waltham, MA: UpToDate; 2020. Available at www.uptodate.com. Accessed April 15, 2020.
22. Napolitano M, Megna M, Balato A, et al. Systemic treatment of pediatric psoriasis: A review. Dermatol Ther (Heidelb). 2016;6(2):125-142. doi:10.1007/s13555-016-0117-6
23. Boehncke W-H, Boehncke S, Tobin A-M, Kirby B. The “psoriatic march”: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303-307. doi:10.1111/j.1600-0625.2011.01261.x
24. Enbrel (etanercept) [package insert]. Thousand Oaks, CA: Immunex; 2013. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103795s5503lbl.pdf. Accessed April 15, 2020.
25. Stelara (ustekinumab) [package insert]. Horsham, PA: Janssen Biotech; 2013. Available at:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761044lbl.pdf. Accessed April 15, 2020.
26. Paller AS, Siegfried EC, Pariser DM, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;74(2):280-287.e1-3.doi:10.1016/j.jaad.2015.09.056
27. Landells I, Marano C, Hsu M-C, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594-603. doi:10.1016/j.jaad.2015.07.00
28. Papp K, Thaçi D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet Lond Engl. 2017;390(10089):40-49. doi:10.1016/S0140-6736(17)31189-3
29. Taltz (ixekizumab) [package insert]. Indianapolis, IN: Eli Lilly and Company. Available at http://uspl.lilly.com/taltz/taltz.html#pi. Accessed April 15, 2020.
30. Watanabe K, Takase K, Ohno S, et al. Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. Mod Rheumatol. 2012;22(3):470-473. doi:10.1007/s10165-011-0521-9
31. Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol. 2016;22(28):6444-6455. doi:10.3748/wjg.v22.i28.6444
32. Song JE, Kim DY. Diagnosis of hepatitis B. Ann Transl Med. 2016;4(18):338. doi:10.21037/atm.2016.09.11
33. Cannizzaro MV, Franceschini C, Esposito M, et al. Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management. Psoriasis (Auckl). 2017;7:35-40.doi:10.2147/PTT.S108209
34. Motaparthi K, Stanisic V, Van Voorhees AS, et al; Medical Board of the National Psoriasis Foundation. From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for
hepatitis B infection prior to initiating anti-tumor necrosis factoralfa inhibitors or other immunosuppressive agents in patients with psoriasis. J Am Acad Dermatol. 2014;70(1):178-186.doi:10.1016/j.jaad.2013.08.049
35. Centers for Disease Control and Prevention. Viral Hepatitis B. Updated March 16, 2020. Available at https://www.cdc.gov/hepatitis/hbv/pdfs/serologicchartv8.pdf. Accessed April 15, 2020.

36. Amin M, No DJ, Egeberg A, Wu JJ. Choosing first-line biologic treatment for moderate-to-severe psoriasis: What does the evidence say? Am J Clin Dermatol. 2018;19(1):1-13. doi:10.1007/s40257-017-0328-3
37. Chiu HY, Chen CH, Wu MS, et al. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol. 2013;169(6):1295-1303.doi:10.1111/bjd.12461
38. Ting SW, Chen YC, Huang YH. Risk of hepatitis B reactivation in patients with psoriasis on ustekinumab. Clin Drug Investig. 2018;38(9):873-880. doi:10.1007/s40261-018-0671-z
39. Duncan JR, Orlowski TJ, Elewski BE. Safety of guselkumab in hepatitis B virus infection. Dermatol Online J. 2019;25(10):13030/qt47h636rx.
40. Chiu HY, Hui RC, Huang YH, et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: A multicentric prospective cohort study. Acta Derm Venereol. 2018;98(9):829-834. doi:10.2340/00015555-2989
41. Feaster B, Cline A, Feldman SR. Secukinumab for psoriasis in a patient with hepatitis B. Dermatol Online J. 2018;24(9):13030/qt58t2f0jh.
42. Peccerillo F, Odorici G, Pellacani G, Conti A. Secukinumab: A positive outcome in a patient with severe psoriasis and HBV-HCV coinfection. Dermatol Ther. 2018;31(4):e12601.doi:10.1111/dth.12601
43. Cosentyx (secukinumab) [package insert] East Hanover, New Jersey: Novartis Pharmaceuticals Corporation. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125504s001s002lbl.pdf. Accessed on April 15, 2020.
44. Nakamura M, Abrouk M, Farahnik B, et al. Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies. Cutis. 2018;101(1):38-56.
45. Menon K, Van Voorhees AS, Bebo BF Jr, et al. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(2):291-299.doi:10.1016/j.jaad.2009.03.047
46. Montes-Torres A, Aparicio G, Rivera R, et al. Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study. J Dermatolog Treat. 2019;30(5):461-465. doi:10.1080/09546634.2018.1535690
47. Bartos G, Cline A, Beroukhim K, et al. Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review. Dermatol Online J. 2018;24(11):13030/qt3db748cg.
48. Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nat Rev Dis Primers. 2016;2:16076. doi:10.1038/nrdp.2016.76
49. Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008;59(2):209-217.doi:10.1016/j.jaad.2008.03.023
50. Mor A, Bingham CO 3rd, Kishimoto M, et al. Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinic. Ann Rheum Dis. 2008;67(4):462-465.doi:10.1136/ard.2007.076406
51. Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43-53. doi:10.1016/j.jaad.2018.06.056
52. Tsai TF, Ho V, Song M, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol. 2012;167(5):1145-1152.doi:10.1111/j.1365-2133.2012.11142.x
53. Lynch M, Roche L, Horgan M, et al. Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis. JAAD Case Rep. 2017;3(3):230-232. doi:10.1016/j.jdcr.2017.02.001
54. Kammüller M, Tsai TF, Griffiths CE, et al. Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin Transl Immunology. 2017;6(8):e152.doi:10.1038/cti.2017.34
55. Ribero S, Licciardello M, Quaglino P, Dapavo P. Efficacy and sSafety of secukinumab in patients with plaque psoriasis and latent tuberculosis. Case Rep Dermatol. 2019;11(Suppl 1):23-28.doi:10.1159/000501989
56. Fowler E, Ghamrawi RI, Ghiam N, et al. Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2020;10.1111/jdv.16254. doi:10.1111/jdv.16254
57. Armstrong AW, Robertson AD, Wu J, et alG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180-1185.doi:10.1001/jamadermatol.2013.5264
58. Jim On SC, Lebwohl M. Barriers imposed by insurance companies to biologic therapy in patients with moderate-to-severe psoriasis. Psoriasis Forum. 2012;18a(4):217-220.doi.org/10.1177/247553031218a00407
59. Aldredge LM, Young MS. Providing guidance for patients with
moderate-to-severe psoriasis who are candidates for biologic therapy: Role of the nurse practitioner and physician assistant. J Dermatol Nurses Assoc. 2016;8(1):14-26.doi:10.1097/JDN.0000000000000185
60. Mullican KA, Francart SA. The role of specialty pharmacy drugs in the management of inflammatory diseases. Am J Health-Sys Pharm. 2016;73(11):821-830. doi.org/10.2146/ajhp150727
61. Johnson C, Zumwalt M, Anderson N. Latex hypersensitivity to injection devices for biologic therapies in psoriasis patients. Cutis. 2019;103(5):299.
62. Poelman SM, Keeling CP, Metelitsa AI. Practical guidelines for managing patients with psoriasis on biologics: An update. J Cutan Med Surg. 2019;23(1 suppl):3S-12S.doi:10.1177/1203475418811347
63. [No author.] Vaccinating immunocompromised patients. Pharmacist’s Letter/Prescriber’s Letter. December 2019.
64. Baumrin E, Van Voorhees A, Garg A, et al. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2019;81(1):102-110.doi:10.1016/j.jaad.2019.03.017